About us

Autolus is a privately held biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer.

Technology

We are applying our broad array of T cell programming technologies and capabilities to engineer precisely targeted controlled and highly active T cell therapies that are designed to better recognise cancer cells, break down their defence mechanisms and attack and kill these cells.

Stock quote


News


Events